Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 16/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | ULK1 | O75385 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21374216 | 0.81 | XPO1 (0.40) | LRRK2CYP1A2ULK1TRPV1 | |
| SCHEMBL27228448 | 0.81 | GAA (0.40) | LRRK2CYP1A2ULK1TRPV1 | |
| SCHEMBL11916180 | 0.81 | LRRK2 (0.42) | LRRK2CYP1A2TRPV1 | |
| SCHEMBL31725504 | 0.80 | TRPV1 (0.37) | LRRK2CYP1A2ULK1TRPV1 | |
| SCHEMBL25529316 | 0.79 | LRRK2 (0.47) | LRRK2CYP1A2ULK1 | |
| SCHEMBL15221838 | 0.79 | LRRK2 (0.60) | LRRK2CYP1A2ULK1 | |
| SCHEMBL31725454 | 0.78 | AURKA (0.54) | LRRK2CYP1A2ULK1MBOAT4 | |
| SCHEMBL31725453 | 0.78 | AURKA (0.54) | LRRK2CYP1A2ULK1MBOAT4 | |
| SCHEMBL13323758 | 0.77 | TRPV1 (0.39) | LRRK2CYP1A2ULK1TRPV1MBOAT4 | |
| SCHEMBL22997711 | 0.77 | TRPV1 (0.37) | LRRK2CYP1A2TRPV1MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235687-A1 | LRRK2 INHIBITORS | Brenig Therapeutics, Inc. (US) | 2025-11-13 | — | — | WO | disclosed |
| CN-118878521-B | Preparation method of LRRK2 inhibitor | 苏州美诺医药科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-118878521-A | Preparation method of LRRK2 inhibitor | 苏州美诺医药科技有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20220125788-A1 | FAK inhibitor and drug combination thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-04-28 | — | — | US | disclosed |
| US-10662195-B2 | Protein kinase conjugates and inhibitors | CELGENE CAR LLC (BM) | 2020-05-26 | — | — | US | disclosed |
| US-10266549-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-8785464-B2 | Pyrimidine derivatives that inhibit FAK/PTK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-20140038993-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20110288109-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | US | disclosed |
| US-20110251174-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-13 | — | — | US | disclosed |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266549-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | LRRK2 657/4885CYP1A2 4542/4885ULK1 1/4885 |
| US-20110288109-A1 | NEW COMPOUNDS | MKI67, CCNA1, CCNT1 | LRRK2 2149/4885CYP1A2 218/4885ULK1 3256/4885 |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | LRRK2 706/4885CYP1A2 4682/4885ULK1 1/4885 |
| US-20170327485-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | LRRK2 3997/4885CYP1A2 3773/4885ULK1 4191/4885 |
| US-20220125788-A1 | FAK inhibitor and drug combination thereof | CD274, PDCD1, PTK2 | LRRK2 408/4885CYP1A2 3094/4885ULK1 880/4885 |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, ADK, TTK | LRRK2 574/4885CYP1A2 3518/4885ULK1 364/4885 |
| US-20110251174-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | AURKA, AURKC, AURKB | LRRK2 708/4885CYP1A2 3043/4885ULK1 1849/4885 |
| US-20070032514-A1 | 2,4-diamino-pyrimidines as aurora inhibitors | AURKA, AURKC, AURKB | LRRK2 708/4885CYP1A2 3043/4885ULK1 1849/4885 |
| US-20140038993-A1 | NEW COMPOUNDS | MKI67, CCNA1, CCNT1 | LRRK2 2137/4885CYP1A2 164/4885ULK1 3331/4885 |
| US-20130281429-A1 | 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS | AURKA, AURKC, AURKB | LRRK2 708/4885CYP1A2 3043/4885ULK1 1849/4885 |
| US-10662195-B2 | Protein kinase conjugates and inhibitors | MAP3K20, ADK, TTK | LRRK2 574/4885CYP1A2 3518/4885ULK1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.